Epigenetics Underpinning the Regulation of the CXC (ELR+) Chemokines in Non-Small Cell Lung Cancer
2011

Chemokines and Epigenetics in Non-Small Cell Lung Cancer

Sample size: 37 publication Evidence: moderate

Author Information

Author(s): Baird Anne-Marie, Gray Steven G., O'Byrne Kenneth J.

Primary Institution: Thoracic Oncology Research Group, Institute of Molecular Medicine, Trinity College, Dublin, Ireland

Hypothesis

The expression of CXC (ELR+) chemokines and their receptors is regulated epigenetically in non-small cell lung cancer (NSCLC).

Conclusion

CXC (ELR+) chemokines are dysregulated in NSCLC, and their balance may be critical in the tumor microenvironment.

Supporting Evidence

  • CXC (ELR+) chemokines are important in neo-vascularisation and metastasis.
  • Histone deacetylase inhibitors can up-regulate CXCL8 in lung cancer cell lines.
  • Expression of many chemokines was found to be downregulated in NSCLC tumors.

Takeaway

This study found that certain chemicals in lung cancer are not working properly, and changing how they are controlled might help treat the cancer better.

Methodology

The study examined the expression of CXC (ELR+) chemokines in NSCLC tumor samples and cell lines using RT-PCR and chromatin immunoprecipitation.

Potential Biases

Potential bias due to the limited sample size and specific patient demographics.

Limitations

The heterogeneity of tumor samples makes it difficult to draw definitive conclusions.

Participant Demographics

14 adenocarcinoma and 23 squamous cell carcinoma patients with early stage NSCLC.

Statistical Information

P-Value

p<0.01 for CXCL1 and CXCL2; p<0.05 for CXCR1.

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0014593

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication